131 related articles for article (PubMed ID: 12908511)
21. Dendritic cell-based vaccines in breast and gynaecologic cancer.
Hernando JJ; Park TW; Kuhn WC
Anticancer Res; 2003; 23(5b):4293-303. PubMed ID: 14666641
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.
De Felice F; Marchetti C; Palaia I; Musio D; Muzii L; Tombolini V; Panici PB
J Immunol Res; 2015; 2015():191832. PubMed ID: 26236750
[TBL] [Abstract][Full Text] [Related]
23. Novel therapies for recurrent ovarian cancer management.
Bhoola SM; Alvarez RD
Expert Rev Anticancer Ther; 2004 Jun; 4(3):437-48. PubMed ID: 15161442
[TBL] [Abstract][Full Text] [Related]
24. [Development of tumor vaccine on gynecologic cancer].
Xu BL; Li Y; Cui H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug; 25(4):487-91. PubMed ID: 12974100
[TBL] [Abstract][Full Text] [Related]
25. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.
De Cesare M; Calcaterra C; Pratesi G; Gatti L; Zunino F; Mènard S; Balsari A
Clin Cancer Res; 2008 Sep; 14(17):5512-8. PubMed ID: 18765543
[TBL] [Abstract][Full Text] [Related]
26. Construction and expression of a single chain antibody mimicing human ovarian cancer antigen CA125.
Li AD; Li Z; Wang YH; Zhang YM; Ma J
Cell Mol Immunol; 2006 Feb; 3(1):59-62. PubMed ID: 16549051
[TBL] [Abstract][Full Text] [Related]
27. Antibodies and vaccines--hope or illusion?
Jäger D; Knuth A
Breast; 2005 Dec; 14(6):631-5. PubMed ID: 16242931
[TBL] [Abstract][Full Text] [Related]
28. Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination.
Liu G; Black KL; Yu JS
Expert Rev Vaccines; 2006 Apr; 5(2):233-47. PubMed ID: 16608423
[TBL] [Abstract][Full Text] [Related]
29. Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature.
Whitworth JM; Alvarez RD
Expert Opin Biol Ther; 2011 Jun; 11(6):751-62. PubMed ID: 21391898
[TBL] [Abstract][Full Text] [Related]
30. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
31. [Progress on the study of ovarian carcinoma vaccine ].
Peng P; Shen J
Zhonghua Fu Chan Ke Za Zhi; 2004 Jul; 39(7):500-2. PubMed ID: 15347482
[No Abstract] [Full Text] [Related]
32. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
Berinstein NL
Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
[TBL] [Abstract][Full Text] [Related]
33. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
34. Twelve immunotherapy drugs that could cure cancers.
Cheever MA
Immunol Rev; 2008 Apr; 222():357-68. PubMed ID: 18364014
[TBL] [Abstract][Full Text] [Related]
35. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.
Meredith RF; Buchsbaum DJ; Alvarez RD; LoBuglio AF
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5643s-5645s. PubMed ID: 17875801
[TBL] [Abstract][Full Text] [Related]
36. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
[TBL] [Abstract][Full Text] [Related]
37. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer.
Adams M; Navabi H; Croston D; Coleman S; Tabi Z; Clayton A; Jasani B; Mason MD
Vaccine; 2005 Mar; 23(17-18):2374-8. PubMed ID: 15755631
[TBL] [Abstract][Full Text] [Related]
38. Antifungal immunotherapy and immunomodulation: a double-hitter approach to deal with invasive fungal infections.
Hamad M
Scand J Immunol; 2008 Jun; 67(6):533-43. PubMed ID: 18397201
[TBL] [Abstract][Full Text] [Related]
39. Trends in therapeutic monoclonal antibodies of cancer.
Shi W; Qu C; Qian Q
Expert Opin Ther Pat; 2007 Sep; 17(9):1047-59. PubMed ID: 20144085
[TBL] [Abstract][Full Text] [Related]
40. [Induction of T cell responses against autologous ovarian cancer by anti-idiotype minibody-pulsed dendritic cells].
Yang WL; Cui H; Feng J; Chang XH; Fu TY; Ye X; Zhang H; Li XP; Wen HW; Feng LM; Tong CR
Ai Zheng; 2004 Dec; 23(12):1639-45. PubMed ID: 15601552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
